PRM 151

Drug Profile

PRM 151

Alternative Names: PRM-151; rhPTX 2; rhSAP; SAP; Serum amyloid P

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Promedior
  • Class Anti-inflammatories; Antifibrotics; Glycoproteins; Recombinant proteins
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars; Myelofibrosis; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Myelofibrosis; Scars
  • Preclinical Lung disorders
  • No development reported Kidney disorders

Most Recent Events

  • 07 Dec 2016 Phase-II clinical trials in Myelofibrosis in Netherlands (IV), United Kingdom (IV), Germany (IV), Italy (IV), Israel (IV), France (IV) (NCT01981850)
  • 02 Dec 2016 Promedior completes enrolment in the phase II trial for Idiopathic pulmonary fibrosis in USA, Netherland, Germany, Belgium, Czech Republic, Spain, Italy, Switzerland and Hungary (NCT02550873) (EudraCT2014-004782-2)
  • 02 Dec 2016 Promedior completes enrolment in the phase II trial for Myelofibrosis in USA, Canada, France, Germany, Israel, Italy, Netherlands, United Kingdom (NCT01981850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top